Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampin on Cabotegravir PK in Healthy Subjects
NCT02411435Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Jul 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabotegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Primary endpoints: Plasma CAB maximum observed concentration and Plasma CAB area under the concentration versus time curve from time zero to infinity. Started Jul 2015; status: completed.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02411435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411435.